Related Experiment Video
Updated: May 14, 2026
11:06
Subretinal Implantation of RPE on a Carrier in Minipigs: Guidelines for Preoperative Preparations, Surgical Techniques, and Postoperative Care
Published on: November 11, 2022
Clocortolone pivalate: a topical corticosteroid with a unique structure
1Mount Sinai Medical Center, New York, NY, USA. wedoderm@yahoo.com
Journal of Drugs in Dermatology : JDD
|February 5, 2013
Summary
Clocortolone pivalate 0.1% cream offers a balanced potency, efficacy, and safety profile for treating steroid-responsive dermatoses. This therapeutic option is well-formulated and versatile for various patient needs.
Area of Science:
- Dermatology
- Pharmacology
- Medicinal Chemistry
Background:
- Topical corticosteroids are mainstays in managing inflammatory skin conditions.
- Balancing efficacy with safety is crucial for long-term topical steroid use.
- Clocortolone pivalate represents a specific molecule engineered for dermatological application.
Purpose of the Study:
- To evaluate the clinical evidence and experience with clocortolone pivalate.
- To highlight the molecule's unique engineering, efficacy, and safety profile.
- To position clocortolone pivalate 0.1% cream as a therapeutic option for steroid-responsive dermatoses.
Main Methods:
- Review of accumulated clinical evidence and experience.
- Analysis of the molecular engineering of clocortolone pivalate.
- Assessment of formulation, efficacy, and safety data.
Main Results:
- Clocortolone pivalate exhibits a favorable balance between potency and safety.
- Documented efficacy has been observed in patients with relevant dermatoses.
- The 0.1% cream formulation is well-characterized.
Conclusions:
- Clocortolone pivalate 0.1% cream is a versatile therapeutic choice.
- Its unique molecular design contributes to a favorable risk-benefit ratio.
- Consideration for patients with steroid-responsive dermatoses is recommended.
Related Concept Videos
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:22Drug Delivery: Miscellaneous Routes
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...